Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04073160
Title TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daniel George, MD

bladder urothelial carcinoma



Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.